Alzheimer's Pipeline Assessment and Insights Report 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Alzheimer's: Pipeline Assessment and Insights" report has been added to ResearchAndMarkets.com's offering.

Alzheimer's: Pipeline Assessment and Insights report delivers an in-depth understanding of the disease, highlights all the pipeline products in different phases of development for the disease including the Suspended products and outlines in detail the drug profiles of key Pipeline therapies in the disease area.

Key Topics Covered:

1 Table of Contents:

1.1 List of Tables

1.2 List of Figures

2 Alzheimer's Disease

2.1 Disease Overview

2.1.1 Disease Definition

2.1.2 Disease Epidemiology

2.1.3 Current Treatment Options

2.1.4 Key unmet needs

3 Pipeline Assessment

3.1 Overview

3.2 Strategic Review of the Pipeline

3.3 Pipeline analysis by Phases of Development

3.3.1 NDA/BLA Filed

3.3.2 Phase III Pipeline

3.3.3 Phase II Pipeline

3.3.4 Phase I Pipeline

3.3.5 Preclinical Pipeline

3.3.6 Discovery Pipeline

3.4 Pipeline Analysis by Mechanism of Action

3.5 Pipeline Analysis by Novelty of Mechanism of Action

3.6 Suspended and Terminated products

3.7 Alzheimer's - Promising Therapies in Pipeline

3.7.1 Aducanumab

3.7.2 Crenezumab

3.7.3 Solanezumab

3.7.4 LMTX

3.7.5 Gantenerumab

3.7.6 BAN2401

3.7.7 Lanabecestat

3.7.8 Elenbecestat

3.7.9 Masitinib

3.7.10 Nuplazid

3.7.11 JNJ-54861911

Companies Mentioned

  • Cystic Fibrosis Foundation
  • Vertex Pharmaceuticals
  • Royalty Pharma
  • Aradigm
  • Chugai Pharmaceutical
  • Roche
  • Pharmstandard
  • PARI Medical Holding
  • Teva Pharmaceutical Industries
  • Dr. Reddy's Laboratories
  • Cipla
  • Lupin
  • Akorn
  • Pharmaxis
  • Gruppo Angelini
  • Phebra
  • PlumeStars
  • Amneal Pharmaceuticals
  • Novartis
  • ProQR Therapeutics
  • Galapagos
  • AbbVie

For more information about this report visit https://www.researchandmarkets.com/research/dj84p2/alzheimers?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Alzheimer's Disease Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Alzheimer's Disease Drugs